My Story
Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship studying DNA repair, Brian realized he enjoyed analyzing other people’s data more than running his own experiments.
Having gotten his first taste of how to analyze stocks as a member of The Motley Fool many years before, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com in 2007.
Brian is currently an analyst for The Fool's Biotech Breakthroughs service. He previously helped launch the Odyssey 2 portfolio in the Fool’s Supernova service, which had a cumulative return of 247% over the 5.5 years it was active, compared to a 152% total return for the S&P 500.
When not writing for The Motley Fool or trade journals, such as Nature Biotechnology and BioWorld, Brian can be found working in his vegetable garden or hanging out at the beach in his hometown of San Diego.
The Motley Fool respects your privacy and strive to be transparent about our data collection practices. We use your information to customize the site for you, to contact you about your membership, provide you with promotional information, and in aggregate to help us better understand how the service is used. For more details, please review our Privacy Policy.
